SANDOZ INC for SANDOZ INC
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report (this page) | Apr 20, 2026 | $140,000 | Replaced |
| 1st Quarter - Amendment | Jul 20, 2026 | $890,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Policies related to the ASP calculation in Medicare Part B Promoting a resilient pharmaceutical supply chain Policies related to serial patent litigation under the Hatch-Waxman Act. Issues related to increasing access to generic and biosimilar medications
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL BARNARD | — |
| KATHLEEN CALLANAN New | Senior Legislative Assistant, Representative Mike Ross |
| JONATHAN KIMBALL | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.